The ExoDx™ Prostate Test
A standalone, exosome-based prostate cancer test delivering a unique data point to help guide the prostate biopsy decision. The ExoDx Prostate test has been included in the NCCN Guidelines since 2019 for early detection of prostate cancer. The ExoDx Prostate test is independent of PSA and other standard of care (SOC) information.
For TeleMedicine visits, check out the At-Home Collection Kit!
Assess prostate cancer risk
Leverages the power of exosomes to detect disease earlier in the progression of prostate cancer
Precisely predictive, clinically convenient
Simple urine test, non-DRE, included in the NCCN guidelines to help guide your patient to biopsy decision
A new standard in prostate risk assessment
Clinical studies demonstrate the ExoDx Prostate test discriminates between high-grade and low-grade prostate cancer and benign disease
A treasure trove of RNA, DNA and protein
Let us help you solve complex clinical and scientific challenges with liquid biopsy, exosome-based technology that is vastly superior to cfDNA and CTCs
ExoDx™ Prostate Test For U.S. Veterans
The ExoDx Prostate test is now available to U.S. Veterans. The Veteran population has a two-fold increased risk of prostate cancer incidence compared to the general population but if detected early, prostate cancer is treatable. The ExoDx Prostate Test (EPI) provides actionable information that aids the prostate biopsy decision for men with PSA in the ‘gray zone’ of 2–10 ng/mL and is not dependent on other clinical risk factors. Learn more about the EPI test including a testimonial of how the ExoDx Prostate test helped a 61-year old man facing a prostate biopsy.
Taking Charge of Your Prostate Health: Download eBook Today.
Industry Workshop Exosome Diagnostics - New Innovations: Use of a liquid biomarker as a risk assessment tool for use in early detection of prostate cancer
Smarter Screening for Prostate Cancer: The Road Forward in 2021 with Dr. Matthew Cooperberg
Prostate Cancer Risk Assessment: Getting Beyond PSA With Dr. Sanoj Punnen
Entering the Chat Room of Cancer Cells - How They Talk and Why We Should Listen
Bio-Techne Announces Publication of ExoDx™ Prostate (IntelliScore) EPI Test Clinical Utility Study
ExoDx Prostate Test: Implications for Value-Based Care with Dr. Judd Moul
Medicare Issues Final Local Coverage Decision for Bio-Techne's ExoDx Prostate (Intelliscore) Test
ExoDx Prostate(IntelliScore) (EPI) Included in National Comprehensive Cancer Network Guidelines for Prostate Cancer Early Detection
Stay in Touch with ExosomeDxJoin our Mailing LIst
Receive updates and scientific advances
Partner with Exosome Diagnostics
Meet Johan and Michael. "With what we know about exosomes, we are the perfect partners for helping pharma partners solve their research problems".
Dr. Johan Skog is the Chief Scientific Officer at ExosomeDx and one of the world’s first scientists to discover exosomes. He immediately saw the opportunity of analyzing the RNA transcriptome profile to stratify patients as to how they respond to treatment. Michael Valentino is Exosome Diagnostic's Scientific Director and knew from a young age he wanted to be part of changing the course of cancer treatment.